SUMMARY In order to evaluate its hemodynamic actions, tocainide, a new orally effective antiarrhythmic drug, was given intravenously over a 15 minute period to 12 patients with compensated left ventricular dysfunction. Doses were 0.5 (4 patients) or 0.75 (8 patients) mg/kg/min. Hemodynamics and drug plasma concentrations were measured at the end and 15 minutes after the end of the infusion. Tocainide infusion produced small but statistically significant TOCAINIDE is a new antiarrhythmic drug which is effective for treating ventricular arrhythmias.' 2 Clinically it is well tolerated at effective doses and it has several desirable pharmacokinetic properties. These include a high oral bioavailability, a low clearance, and a long plasma half-life.3 There is a wide range of intersubject variability in the relationship between antiarrhythmic effect and plasma concentration. For most patients the antiarrhythmic effects are observed at a plasma concentration above 6 ,4g/ml.1 I In our clinical experience, tocainide has been well tolerated hemodynamically, including patients with compensated left ventricular dysfunction. Since there has been no formal evaluation of tocainide's hemodynamic effects in man, the present study was performed to evaluate the hemodynamic effects of acute administration of intravenous tocainide in patients.
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Methods
Twelve male patients with suspected or known coronary artery disease were studied at the time of diagnostic cardiac catheterization. The nature of the study and all risks were explained to the patients, and written informed consent was obtained. The protocol was approved by the Stanford Medical Committee on the Use of Human Subjects in Research. The age of the patients ranged from 40 to 67 years. Four patients were on chronic digitalis therapy at the time of this study. Six patients were taking propranolol; this medication was withheld before cardiac catheterization in three of the six patients. At the time of diagnostic cardiac catheterization, right atrial, right ventricular, pulmonary artery, and pulmonary capillary wedge phasic and electronically meaned pressures were recorded with a 7 or 8F endhole catheter connected to a Statham P23Db pressure trans- ducer. Systemic arterial and left ventricular pressure tracings were recorded by percutaneous catheterization of the femoral artery with a 6.7F end-hole or multiple side-hole catheter connected to a Micron MP-15 transducer. The first derivative of the left ventricular pressure tracing (dp/dt) was increases in the pulmonary and systemic vascular resistance, aortic and pulmonary arterial pressure, and left and right ventricular enddiastolic pressure. There was no significant change in left ventricular dp/dt, heart rate, or cardiac index. In patients with compensated left ventricular dysfunction, tocainide produces a small rise in vascular resistance and arterial pressure. Overall cardiac function is maintained with a small increase in left ventricular end-diastolic pressure.
obtained by electronic differentiation. The zero pressure reference level was taken at mid-chest. Cardiac output was determined by the Fick technique, using the arteriovenous 02 difference and a 5-minute collection of expired air. After routine cardiac catheterization, each patient performed exercise using a bicycle ergometer, and underwent left ventriculography using a 50 cc bolus of meglumine diatrizoate and sodium diatrizoate administered over three or four cardiac cycles. Approximately 30 minutes after the ventriculography and after the left ventricular end-diastolic pressure measurement, aortic pressure and pulmonary artery pressure had returned to control values, tocainide was administered, using a Harvard infusion pump via a 19-gauge scalp vein needle inserted into an antecubital vein. The dose of tocainide administered to four patients was 0.50 mg/kg/min and 0.75 mg/kg/min to eight patients. Tocainide was provided as a 50 mg/ml solution and was diluted to a total volume of approximately 50 ml for each patient. Tocainide was infused into an intravenous solution of 5% dextrose in water running at a rate of 200 cc per hour for the 15-minute period of the infusion and for five minutes following the infusion. Blood samples for tocainide analysis were collected from the antecubital vein of the arm not used for drug infusion. A 30 cc blank was obtained prior to drug infusion and 10 cc samples were obtained at 1, 3, 5, 7, 9, 11, 13, 15, 17, 20, 25, 30, 40 , and 60 minutes after initiation of the infusion. Samples were immediately placed in heparinized vacutainer tubes. Samples were spun at the end of the study, and the plasma frozen until subsequent analysis. The timing of the entire study was carried out using a precision timer. Tocainide plasma concentrations were analyzed using previously described high pressure liquid chromatographic assay. 5 During the tocainide infusion, systemic arterial pressure and heart rate were monitored continuously and recordings were made at 5 and 10 minutes after the onset of the infusion. At fig. 2a) . The rise in systemic arterial pressure appeared to be due to an increase in systemic vascular resistance from 15.9 ± 3.6 resistance units (RU) to 17.8 5.1 RU at 15 minutes (P < 0.025) and to 17.6 ± 4.7 RU at 30 minutes (P < 0.02) (fig. 2b ). Although these measurements tended to rise during infusion and fall minimally by 15 minutes post-infusion, no strong correlation could be made between the percent change in mean arterial pressure and plasma tocainide concentration. The pulmonary circulation showed similar rises in pulmonary arterial pressure ( fig. 3a) and the pulmonary vascular resistance ( fig. 3b ) during tocainide infusion.
Cardiac Effects
Tocainide caused no change in heart rate. There was a statistically significant rise in left ventricular end-diastolic pressure ( fig. 4a) Side Effects Six patients experienced subjective symptoms during the study. One patient experienced angina pectoris shortly after I E E 0 wU IJ a the infusion was terminated, at a time when plasma concentration was 4.7 gg/ml. He had had several other spontaneous episodes prior to tocainide and had a long history of stable severe rest angina. It was not possible to state for certain whether his angina was precipitated by tocainide. Five patients had symptoms definitely related to tocainide infusion. One patient expressed a sensation of facial coldness and cold breath at 10 min, at a time when plasma concentration (CP) was 15 ,g/ml. Another experienced warm lips at 11 min of infusion (CP = 9.34 ,ug/ml) and cold lips at 12 min (CP = 10.0 ,g/ml). The third patient experienced slight confusion at 7 min (CP = 9.3 ,ug/ml), difficulty in focusing at 8 min (CP = 10.0 ,g/ml), warmth of chest and arms at 9 min (CP = 11.9 Ag/ml), nausea at 15 min (CP = 17. 5 ,gg/ml), generalized warmth at 16 min (CP = 17 ,ug/ml) and one single episode of vomiting at one hour (CP = 6.8 gg/ml). A fourth patient noted a cold throat at 3 min (CP = Tocainide's effect on left ventricular dp/dt. Although left ventricular dp/dt fell slightly during the drug infusion, this change was not statistically significant. 
Discussion
The patients participating in this hemodynamic study had considerable left ventricular dysfunction. Ten of the patients had coronary artery disease, including left main coronary arterial lesions in two patients. Eight patients demonstrated contraction abnormalities including dyskinetic left ventricular aneurysms in four patients. Although all patients were compensated at rest, the patients as a group demonstrated severe left ventricular dysfunction during exercise. None of these patients had experienced cardiac arrest or major ventricular arrhythmias. However, they are hemodynamically similar to many of the patients who have had, or are at high risk of developing, serious ventricular arrhythmias. These types of patients may in the future be candidates for chronic antiarrhythmic therapy, with a goal of preventing sudden cardiac death.
Tocainide was well-tolerated hemodynamically by these patients. The primary effect was a small rise in vascular resistance, resulting in small increases in aortic and pulmonary arterial pressures. There was a small rise in left ventricular end-diastolic pressure observed immediately at the end of the tocainide infusion in these patients, which had returned to control by 15 minutes post-infusion. This rise may have resulted from a direct myocardial depressant effect or from the small increase in peripheral vascular resistance. Although there was a slight reduction in left ventricular dp/dt at the end of the infusion, this change was not statistically significant. The failure of the left ventricular stroke work index to rise, and the fall or absence of rise in left ventricular dp/dt, despite the increases in left ventricular end-diastolic pressure and aortic pressure, may represent a minor depressant effect of tocainide. However these changes may represent the common response of a compromised left ventricle to increased afterload and may or may not represent added depressant effect of tocainide on the myocardium.' At rest, any adverse effects on left ventricular function appear to be small and may be clinically unimportant, since all patients were able to maintain cardiac output throughout the period of tocainide infusion. However, it must be emphasized that in some individual patients marked rises in left ventricular end-diastolic pressure may occur. Additionally, although the increases were well tolerated at rest, it is possible that for some patients left ventricular end-diastolic pressure may rise to intolerable levels with exercise. We have shown previously that tocainide is effective for suppressing premature ventricular contractions in patients at plasma concentrations ranging between 6 and 10 ,ug/ml.' Careful analysis of concentration response data for individual patients suggests a wide range of intersubject variability in the plasma concentration necessary for reducing premature ventricular contractions.4 Both individual patients and the group as a whole showed a relationship between antiarrhythmic effect and tocainide plasma concentration. The infusion rates used in the present study were chosen to provide tocainide concentrations in the range that was clinically tolerated and proved effective during our studies of oral tocainide administration.
The importance of studying antiarrhythmic drugs at plasma concentrations similar to those required for antiarrhythmic activity, and drug administration at rates that are not excessive, is apparent from recent experiences with procainamide and quinidine. The hemodynamic effects of both these antiarrhythmic agents were initially evaluated after very rapid administration of the drugs. This frequently resulted in severe hypotension and profound myocardial depression. Although plasma concentrations were rarely described, it is quite likely that very high plasma concentrations were transiently achieved during the administration of these drugs. More recent studies using slower infusion rates to achieve plasma concentrations in the clinically effective range suggest that although both drugs are associated with a potentially clinically important fall in blood pressure, ' There were a large number of subjective responses to tocainide infusion. These occurred over a wide range of plasma concentrations. In many patients, these occurred early or midway through the infusion and did not worsen as more drug was infused. The side effects were transient in all instances. The most frequent complaints were related to hot and cold sensations. For the most part, these side effects were very mild and would not have limited the clinical usefulness of the drug during intravenous administration. The occurrence of a wide range of subjective complaints over a relatively wide range of plasma concentrations is similar to our experiences during oral therapy with tocainide.1
In summary, tocainide, when given as an intravenous infusion achieving plasma concentrations in the range required for premature ventricular contraction suppression during oral therapy, caused small elevations in pulmonary and systemic vascular resistances and in mean systemic and pulmonary arterial pressures. There was a small rise in left and right ventricular end-diastolic pressures, but overall cardiac function was not significantly depressed. The observed changes were small and may have little clinical significance for most patients, including those with compensated ventricular dysfunction. The data suggest, however, that the drug should be used with caution in patients with pulmonary or systemic hypertension or uncompensated left or right ventricular failure. Further studies will be required in these patient populations to determine the safety of intravenous tocainide. Finally, it must be recognized that the present study was an acute intravenous intervention study and its relationship to hemodynamic effects seen during chronic oral therapy is unknown.
